Rezolute, Inc. (RZLT) has a MoatMap StockRank of 7/100 based on Quality (38/100), Value (35/100), and Momentum (13/100) factor scores. The current signal is STRONG SELL. Rezolute is a clinical-stage biopharmaceutical company focused on orphan diseases. It does not meet our fundamental criteria for positive owner earnings, high capital return, or established economic moats, making it too speculative for our concentrated book.
Rezolute, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for rare metabolic diseases, with its lead candidate, RZ358, targeting congenital hyperinsulinism (CHI). The company addresses severe unmet medical needs where therapeutic options are limited, with its pipeline targeting orphan diseases that may benefit from expedited regulatory processes and market exclusivity. Rezolute is a biotechnology firm concentrating on developing specialized treatments for rare diseases to serve underserved patient populations.
| Price | $3.90 |
| Market Cap | $315M |
| P/E (Forward) | -7.20 |
| Price/Book | 3.65 |
| Return on Equity | -81.7% |
| Return on Invested Capital | -48.8% |
| Debt/Equity | 0.95 |
| Gross Margin | 0.0% |
| Operating Margin | 0.0% |
| Free Cash Flow | $-44M |
Rezolute, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).